Allosteric receptor modulation is an attractive concept in drug targeting because it offers
important potential advantages over conventional orthosteric agonism or antagonism …

Glutamatergic transmission in schizophrenia: from basic rese... : Current Opinion in Psychiatry
Glutamatergic transmission in schizophrenia: from basic research to clinical practice : Current …

Metabotropic glutamate (mGlu) receptors respond to glutamate, the major excitatory
neurotransmitter in the mammalian brain, mediating a modulatory role that is critical for …

Accumulating evidence suggests that selective M 4 muscarinic acetylcholine receptor
(mAChR) activators may offer a novel strategy for the treatment of psychosis. However …

Ketamine has recently gained significant attention owing to its psychotomimetic and more
recently discovered rapid antidepressant-like properties. 1H-[13C]-nuclear magnetic …

The pharmacological MRI (phMRI) technique is being increasingly used in both pre-clinical
and clinical models to investigate pharmacological effects on task-free brain function …

Ketamine acts as an N-methyl-D-aspartate receptor antagonist and evokes psychotomimetic
symptoms resembling schizophrenia in healthy humans. Imaging markers of acute ketamine …

The pituitary neuropeptide oxytocin promotes social behavior, and is a potential adjunct
therapy for social deficits in schizophrenia and autism. Oxytocin may mediate pro-social …

Evidence for prefrontal cortical (PFC) GABAergic dysfunction is one of the most consistent
findings in schizophrenia and may contribute to cognitive deficits. Recent studies suggest …

Although early clinical observations implicated dopamine dysfunction in the neuropathology
of schizophrenia, accumulating evidence suggests that multiple neurotransmitter pathways …